Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.
Tonix Pharmaceuticals Holding Corp. has been awarded up to $34 million over 5 years under a contract with the U.S. Department of Defense (DoD)’s Defense Threat Reduction Agency (DTRA).
Nexsen Biotech Pty Ltd. developed a rapid diagnostic test for Group B Streptococcus, a highly prevalent and potentially fatal bacteria that is the single largest maternal health problem faced by pregnant mothers.
Shigella flexneri is the leading cause of endemic diarrhea and dysentery in some countries with low-to-middle incomes. There is still a lack of a licensed vaccine against this pathogen.
Researchers at The Scripps Research Institute and the IAVI Neutralizing Antibody Center are developing a novel experimental vaccine targeting the germline to stimulate precursor B cells and produce broadly neutralizing antibodies (bnAbs) against the membrane-proximal external region (MPER) of the gp41 protein found in the HIV-1 envelope.
Preliminary data show Biotron Ltd.’s lead compound BIT-225 met the primary objectives of the phase II BIT225-011 trial, a longitudinal, open-label trial designed to characterize the effect of the compound added to ongoing, suppressive antiretroviral therapy in HIV-1-infected, treatment-experienced patients who achieved only partial immune reconstitution.
New research has pinpointed gene signatures that determine what immune responses will be activated in the development of sepsis, pointing to novel targets and opening the way for the stratification of clinical trials and for patients to be treated on the basis of their immune response, rather than their symptoms.
On the heels of a $7 million seed round, Singapore-based medical technology startup Thrixen Pte Ltd. is accelerating development of its diagnostic technology platform that has the potential to perform multiplex diagnostic tests at the point of care.
Merck Sharp & Dohme LLC has described 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2 infection (COVID-19).
Aligos Therapeutics Inc. have discovered two novel non-heteroaryldihydropyrimidine (HAP) class A capsid assembly modulators (CAM-A) – ALG-006746 and ALG-006780 – which are being developed for the treatment of hepatitis B virus (HBV) infection.
RSS
